

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

ANNOUNCEMENT ON RESULTS OF SUBSIDIARY

Reference is made to the announcement (the “**Announcement**”) dated 27 October 2016 and published by Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”), a subsidiary of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) and whose shares are listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (stock code: 8138), in relation to the third quarterly results of Tong Ren Tang Chinese Medicine and its subsidiaries for the nine months ended 30 September 2016.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following unaudited financial information of Tong Ren Tang Chinese Medicine and its subsidiaries for the nine months ended 30 September 2016 as set out in the Announcement.

CONDENSED CONSOLIDATED INCOME STATEMENT

	Unaudited	
	Nine months ended	
	30 September	
	2016	2015
	HK\$'000	HK\$'000
Revenue	808,242	715,370
Cost of sales	(212,233)	(222,341)
Gross profit	596,009	493,029
Distribution and selling expenses	(110,343)	(103,979)
General and administrative expenses	(69,795)	(61,633)
Other gains	2,655	1,343
Operating profit	418,526	328,760
Finance income	6,006	7,381
Finance costs	(30)	(862)
Finance income, net	5,976	6,519
Share of loss of investments accounted for using the equity method	(2,180)	(1,253)
Profit before income tax	422,322	334,026
Income tax expense	(75,228)	(62,976)
Profit for the period	347,094	271,050
Profit attributable to:		
Owners of the Company	333,832	257,224
Non-controlling interests	13,262	13,826
	347,094	271,050
Earnings per share attributable to owners of the Company (expressed in HK\$ per share)		
Basic and diluted	0.40	0.31

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Unaudited	
	Nine months ended	
	30 September	
	2016	2015
	HK\$'000	HK\$'000
Profit for the period	347,094	271,050
Other comprehensive income:		
<i>Item that may be subsequently reclassified to profit or loss</i>		
Currency translation differences	3,425	(18,133)
Other comprehensive (loss)/income for the period	3,425	(18,133)
Total comprehensive income for the period	350,519	252,917
Attributable to:		
Owners of the Company	335,706	243,459
Non-controlling interests	14,813	9,458
Total comprehensive income for the period	350,519	252,917

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Unaudited								
	Attributable to owners of the Company								
	Share capital HK\$'000	Merger reserve HK\$'000	Other reserve HK\$'000	Statutory reserve HK\$'000	Exchange reserve HK\$'000	Retained earnings HK\$'000	Total HK\$'000	Non-controlling interests HK\$'000	Total equity HK\$'000
At 1 January 2015	867,363	(13,124)	742	2,927	(2,549)	630,390	1,485,749	51,112	1,536,861
Comprehensive income									
Profit for the period	-	-	-	-	-	257,224	257,224	13,826	271,050
Other comprehensive income									
Currency translation differences									
— the Group	-	-	-	-	(11,265)	-	(11,265)	(4,368)	(15,633)
— Joint ventures and an associate	-	-	-	-	(2,500)	-	(2,500)	-	(2,500)
Total comprehensive income	-	-	-	-	(13,765)	257,224	243,459	9,458	252,917
Transactions with owners in their capacity as owners									
Transfer of retained earnings to statutory reserve	-	-	-	1,691	-	(1,691)	-	-	-
Dividends relating to 2014	-	-	-	-	-	(83,710)	(83,710)	-	(83,710)
Issue of ordinary shares relating to business combination	71,426	-	-	-	-	-	71,426	-	71,426
Capital injection to subsidiaries	-	-	-	-	-	-	-	3,817	3,817
Non-controlling interests arising from acquisition of a subsidiary	-	-	-	-	-	-	-	21,144	21,144
Change in ownership interest in a subsidiary without change of control	-	-	88	-	-	-	88	921	1,009
Total transactions with owners in their capacity as owners	71,426	-	88	1,691	-	(85,401)	(12,196)	25,882	13,686
At 30 September 2015	938,789	(13,124)	830	4,618	(16,314)	802,213	1,717,012	86,452	1,803,464
At 1 January 2016	938,789	(13,124)	830	4,130	(14,643)	899,726	1,815,708	93,207	1,908,915
Comprehensive income									
Profit for the period	-	-	-	-	-	333,832	333,832	13,262	347,094
Other comprehensive income									
Currency translation differences									
— the Group	-	-	-	-	1,390	-	1,390	1,551	2,941
— Joint ventures	-	-	-	-	484	-	484	-	484
Total comprehensive income	-	-	-	-	1,874	333,832	335,706	14,813	350,519
Transactions with owners in their capacity as owners									
Transfer of retained earnings to statutory reserve	-	-	-	1,375	-	(1,375)	-	-	-
Dividends relating to 2015	-	-	-	-	-	(108,822)	(108,822)	(10,985)	(119,807)
Capital injection to subsidiaries	-	-	-	-	-	-	-	11,397	11,397
Total transactions with owners in their capacity as owners	-	-	-	1,375	-	(110,197)	(108,822)	412	(108,410)
At 30 September 2016	938,789	(13,124)	830	5,505	(12,769)	1,123,361	2,042,592	108,432	2,151,024

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Gao Zhen Kun
Chairman of the Board

Beijing, the PRC
27 October 2016

As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gong Qin, Mr. Gu Hai Ou, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.